Skip to main content
Midas Edge

Praxis Precision Medicines Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

PRAX$337.59+1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Comprehensive Loss for

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Amounts in thousands)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2024202320242023
Net loss$(51,910)$(24,632)$(124,140)$(96,399)
Change in unrealized gain on marketable securities, net of tax1,402—1,331173
Comprehensive loss$(50,508)$(24,632)$(122,809)$(96,226)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Amounts in thousands, except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Income (Loss) · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 20238,791,877$13$723,577$(653,921)$—$69,669
Stock-based compensation expense——14,475——14,475
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $10,8363,802,025—161,649——161,649
Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $376209,852—6,169——6,169
Issuance of common stock from a collaboration and license agreement443,253—17,265——17,265
Vesting of restricted stock units11,095—————
Shares withheld for taxes for vesting of restricted stock units(3,689)—(137)——(137)
Issuance of common stock upon exercise of stock options3,634—143——143
Change in unrealized gain on marketable securities, net of tax————33
Net loss———(39,553)—(39,553)
Balance at March 31, 202413,258,047$13$923,141$(693,474)$3$229,683
Stock-based compensation expense——5,878——5,878
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $14,0133,849,5581215,987——215,988
Issuance of common stock from exercise of pre-funded warrants622,123—————
Issuance of common stock under employee stock purchase plan25,146—311——311
Vesting of restricted stock units726—————
Shares withheld for taxes for vesting of restricted stock units(242)—(13)——(13)
Issuance of common stock upon exercise of stock options148—4——4
Change in unrealized loss on marketable securities, net of tax————(74)(74)
Net loss———(32,677)—(32,677)
Balance at June 30, 202417,755,506$14$1,145,308$(726,151)$(71)$419,100
Stock-based compensation expense——12,432——12,432
Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $7025,189—1,442——1,442
Issuance of common stock from exercise of stock options4,971—201——201
Vesting of restricted stock units51—————
Shares withheld for taxes for vesting of restricted stock units(20)—(1)——(1)
Change in unrealized loss on marketable securities, net of tax————1,4021,402
Net loss———(51,910)—(51,910)
Balance at September 30, 202417,785,697$14$1,159,382$(778,061)$1,331$382,666

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)

(Amounts in thousands, except share data)

Common Stock1 · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Loss · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 20223,292,163$5$606,918$(530,644)$(173)$76,106
Stock-based compensation expense——7,593——7,593
Issuance of common stock from at-the-market public offerings, net of commission costs of $560560,253118,095——18,096
Vesting of restricted stock units11,516—————
Shares withheld for taxes for vesting of restricted stock units(2,875)—(127)——(127)
Issuance of common stock upon exercise of stock options2,970—101——101
Change in unrealized loss on marketable securities, net of tax————154154
Net loss———(37,455)—(37,455)
Balance at March 31, 20233,864,027$6$632,580$(568,099)$(19)$64,468
Stock-based compensation expense——5,775——5,775
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $4,4844,296,646663,433——63,439
Issuance of common stock from at-the-market public offerings, net of issuance costs392,54116,031——6,032
Issuance of common stock under employee stock purchase plan15,663—208——208
Vesting of restricted stock units720—————
Shares withheld for taxes for vesting of restricted stock units(249)—(4)——(4)
Change in unrealized loss on marketable securities, net of tax————1919
Net loss———(34,312)—(34,312)
Balance at June 30, 20238,569,348$13$708,023$(602,411)$—$105,625
Stock-based compensation expense——5,763——5,763
Vesting of restricted stock units233—————
Shares withheld for taxes for vesting of restricted stock units(70)—(1)——(1)
Issuance of common stock upon exercise of stock options311—1——1
Net loss———(24,632)—(24,632)
Balance at September 30, 20238,569,822$13$713,786$(627,043)$—$86,756

1 Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.